drugset / Trial / NCT03393520

Assessment of the Efficacy, Safety, and Tolerability of AVP-786 (Deudextromethorphan Hydrobromide [d6-DM]/Quinidine Sulfate [Q]) for the Treatment of Agitation in Patients With Dementia of the Alzheimer's Type

NCT03393520

RandomizedParallel-groupQuadruple-blindTreatment

Summary

This study will be conducted to evaluate the efficacy, safety, and tolerability of AVP-786 compared to placebo, for the treatment of agitation in participants with dementia of the Alzheimer's type.

Timeline

Start
2017-10-13
Primary completion
2023-11-17
Completion
2023-12-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Deudextromethorphan Unknown Oral
Subject Quinidine Small molecule Oral

Indications

No indication recorded.